T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF

Aurelija Abraityte, Pal Aukrust, Lei Kou, Inder S. Anand, James Young, John J. V. Mcmurray, Dirk J. van Veldhuisen, Lars Gullestad, Thor Ueland*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

7 Citaten (Scopus)
33 Downloads (Pure)


BackgroundActivated leukocytes may contribute to the development and progression of heart failure (HF). We investigated the predictive value of circulating levels of stable and readily detectable markers reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in HF patients with reduced ejection fraction (HFrEF).MethodsThe association between baseline plasma levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying effects and interaction with darbepoetin alfa treatment were also assessed.ResultsAll leukocyte markers, except granulysin, were associated with the primary outcome and all-cause death in univariate analysis (all p

Originele taal-2English
Pagina's (van-tot)133-141
Aantal pagina's9
TijdschriftClinical Research in Cardiology
Nummer van het tijdschrift2
StatusPublished - feb.-2019

Citeer dit